Not logged in...
About USC Norris
FAQ - Trials
Contact Us - Trials
Support USC Norris
» Contact Us
If you are a patient, please contact
The Doctors of USC
Phase II Trial of the Akt Inhibitor MK-2206 plus Erlotinib (OSI-774) in Patients with Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) with Erlotinib Therapy.
Closed to Accrual with Ongoing Follow-up
Defintions of terms and FAQ about clinical trials.
Barbara Gitlitz, M.D.
Other Trial Staff:
Charlean Ketchens, R.N., Lagrimas Ilagan, D.M., Gina Tse, R.N., Eduardo Mejia, D.M.
to see study documents.
Click here to see trial eligibility criteria and further details at ClinicalTrials.gov
For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or
To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.